![]() The AccuCinch System is an investigational device designed to augment the existing care cardiologists provide their heart failure (HF) patients. Tucker qualified as a chartered accountant in the UK while at Ernst & Young and holds a BS in mathematics from the University of Bristol, England.Ībout the AccuCinch ® Ventricular Restoration System He also held similar positions at Nuvelo and IntraBiotics Pharmaceuticals. Previously, Tucker served as vice president of finance at Sunesis Pharmaceuticals and as principal accounting officer at CymaBay Therapeutics. Tucker is also president and chairman of the Board of the Northern California Chapter of the Association of Bioscience Financial Officers, a position he has held since 2017. Prior to joining Ancora Heart, he served as vice president of finance at Atara Biotherapeutics, Inc., which he joined in 2015. Tucker brings nearly 20 years of experience providing financial leadership for life sciences companies to his role as chief financial officer. I believe that the AccuCinch System has great potential as a treatment option for patients with heart failure and look forward to this opportunity to provide financial leadership to the company." "The core values of the Ancora team, which are focused on helping patients live healthier lives, align strongly with my own. Last month, Cardiac Dimensions made a serious play for FMR and announced it raised $39 million to build strong clinical evidence for its Carillon Mitral Contour System."Ancora Heart is at a very exciting point in its growth pathway, and I am excited to be joining the team at this stage," said Tucker. Edwards gained access to Cardioband through its $340 million plus milestone payments acquisition of Valtech Cardio Ltd. ![]() Irvine, CA-based Edwards competes in the FMR market with the Cardioband device. The company completed its clinical trial for this indication and it is speculated the firm could present data at the upcoming Transcatheter Cardiovascular Therapeutics meeting in September. ![]() Really what we’re looking to do is target that big clinical gap between a CRT and a transplant.”Īncora Heart could face off against stiff competition in the FMR market.Ībbott is seeking to gain FDA approval for an FMR indication for its MitraClip. You have this long kind of clinical chasm or gap before you end up with an LVAD or a transplant. “And after that you’re really out of options for a heart failure perspective. “When you think about the heart failure treatment algorithm, patients get on medical therapy and eventually if it’s required they’ll have a CRT,” he said. The company could file for a pivotal IDE sometime in 2019. “Not too far after that, we’ll submit another protocol to FDA focusing on patients who have had a prior mitral valve intervention that’s reoccurred because the left ventricle had to continue to dilate.” “We’ll be submitting an additional protocol to FDA very shortly that will focus on heart failure,” Closs said. The company said early findings show Ancora Heart’s technology could have some benefit for treating heart failure patients. ![]() is to continue to enroll in that study, which the primary endpoint or primary completion is FMR,” Closs said. ![]() The device can realign the geometry of the valvular apparatus, so it can function more efficiently. Our approach is to target the fundamental cause of FMR, which is a dilated dysfunctional left ventricle.”AccuCinch is a transfemoral access catheter-based approach. “In the traditional FMR market technology is all focused on the valve, and we know the fundamental problem is the left ventricle is dilated and it has changed the geometry of the valve. “The AccuCinch System is a left ventricular repair technology and it really is a new category and class of therapy,” Jeff Closs, president and CEO of Ancora Heart, told MD+DI. Ancora Heart said it can now enroll a second group of patients and expand to 15 heart centers across the U.S. The Santa Clara, CA-based company came closer to its goal to participate in the market after it received FDA approval to expand the enrollment for an early feasibility study of the AccuCinch. Ancora Heart said FDA has approved an expansion of the company’s feasibility study to evaluate the AccuCinch Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR).Īncora Heart is making a play for the functional mitral regurgitation (FMR) treatment market – which is currently populated by medtech juggernauts Abbott Laboratories and Edwards Lifesciences. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |